blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2578231

EP2578231 - ANTITUMOR T CELL RESPONSE ENHANCER [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  23.09.2022
Database last updated on 28.05.2024
FormerGrant of patent is intended
Status updated on  01.06.2022
FormerExamination is in progress
Status updated on  06.08.2021
FormerGrant of patent is intended
Status updated on  25.03.2021
FormerExamination is in progress
Status updated on  21.12.2016
Most recent event   Tooltip17.05.2024New entry: Date of oral proceedings 
Applicant(s)For all designated states
Chugai Seiyaku Kabushiki Kaisha
5-1, Ukima 5-chome Kita-ku
Tokyo 115-8543 / JP
For all designated states
National University Corporation Hokkaido University
Kita 8-jyo Nishi 5-chome
Kita-ku
Sapporo-shi
Hokkaido 060-0808 / JP
[2022/26]
Former [2013/15]For all designated states
Chugai Seiyaku Kabushiki Kaisha
5-1, Ukima 5-chome Kita-ku
Tokyo 115-8543 / JP
For all designated states
National University Corporation Hokkaido University
8, Nishi 5 cho-me, Kita 8 jyo Kita-ku
Sapporo-shi, Hokkaido 0600808 / JP
Inventor(s)01 / NISHIMURA, Takashi
National University Corporation
Hokkaido University
Kita 8-jyo Nishi 5-chome
Kita-ku
Sapporo-shi Hokkaido 060-0808 / JP
 [2013/15]
Representative(s)Simmons & Simmons LLP (Munich), et al
Lehel Carré
Thierschplatz 6
80538 Munich / DE
[N/P]
Former [2022/43]Lahrtz, Fritz, et al
Simmons & Simmons LLP
Prinzregentenstraße 68
81675 München / DE
Former [2013/15]Bösl, Raphael Konrad
Isenbruck Bösl Hörschler LLP Patentanwälte Prinzregentenstrasse 68
81675 München / DE
Application number, filing date11786748.127.05.2011
[2022/43]
WO2011JP62209
Priority number, dateJP2010012295128.05.2010         Original published format: JP 2010122951
[2013/15]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011149051
Date:01.12.2011
Language:JA
[2011/48]
Type: A1 Application with search report 
No.:EP2578231
Date:10.04.2013
Language:EN
[2013/15]
Type: B1 Patent specification 
No.:EP2578231
Date:26.10.2022
Language:EN
[2022/43]
Search report(s)International search report - published on:JP01.12.2011
(Supplementary) European search report - dispatched on:EP02.10.2013
ClassificationIPC:A61K39/395, C07K16/28, A61P43/00, A61P35/00, A61K31/7068, A61K45/06
[2021/15]
CPC:
A61K31/7068 (EP,US); A61K39/3955 (US); A61K39/39558 (EP,US);
A61K45/06 (EP,US); A61P35/00 (EP); A61P43/00 (EP);
C07K16/2815 (EP,US); C07K16/2866 (EP,US) (-)
C-Set:
A61K31/7068, A61K2300/00 (EP,US);
A61K39/39558, A61K2300/00 (US,EP)
Former IPC [2013/44]A61K39/395, A61K31/7068, A61P35/00, A61P43/00, C07K16/28
Former IPC [2013/15]A61K39/395, A61K31/7068, A61P35/00, A61P43/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/15]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ANTITUMOR-T-ZELLEN-REAKTIONSVERSTÄRKER[2013/15]
English:ANTITUMOR T CELL RESPONSE ENHANCER[2013/15]
French:AGENT AMÉLIORANT LA RÉPONSE DE LYMPHOCYTES T ANTI-TUMORAUX[2013/15]
Entry into regional phase06.12.2012Translation filed 
06.12.2012National basic fee paid 
06.12.2012Search fee paid 
06.12.2012Designation fee(s) paid 
06.12.2012Examination fee paid 
Examination procedure06.12.2012Examination requested  [2013/15]
28.04.2014Amendment by applicant (claims and/or description)
02.07.2014Despatch of a communication from the examining division (Time limit: M06)
12.01.2015Reply to a communication from the examining division
31.07.2015Despatch of a communication from the examining division (Time limit: M06)
05.02.2016Reply to a communication from the examining division
05.09.2016Despatch of a communication from the examining division (Time limit: M06)
02.03.2017Reply to a communication from the examining division
10.10.2018Despatch of a communication from the examining division (Time limit: M08)
15.05.2019Reply to a communication from the examining division
16.09.2019Despatch of a communication from the examining division (Time limit: M06)
28.05.2020Reply to a communication from the examining division
26.03.2021Communication of intention to grant the patent
05.08.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
18.08.2021Despatch of a communication from the examining division (Time limit: M05)
04.01.2022Reply to a communication from the examining division
02.06.2022Communication of intention to grant the patent
20.09.2022Fee for grant paid
20.09.2022Fee for publishing/printing paid
20.09.2022Receipt of the translation of the claim(s)
Divisional application(s)EP22192455.8  / EP4115906
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  02.07.2014
Opposition(s)Opponent(s)01  25.07.2023  26.07.2023  ADMISSIBLE
Gedeon Richter Pharma GmbH
Robert-Bosch-Str. 11B
63225 Langen / DE
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 [2023/35]
09.08.2023Invitation to proprietor to file observations on the notice of opposition
18.12.2023Reply of patent proprietor to notice(s) of opposition
25.04.2024Cancellation of oral proceeding that was planned for 08.11.2024
08.11.2024Date of oral proceedings
25.11.2024Date of oral proceedings
Fees paidRenewal fee
27.05.2013Renewal fee patent year 03
21.03.2014Renewal fee patent year 04
21.05.2015Renewal fee patent year 05
20.05.2016Renewal fee patent year 06
23.05.2017Renewal fee patent year 07
25.05.2018Renewal fee patent year 08
23.05.2019Renewal fee patent year 09
30.03.2020Renewal fee patent year 10
18.05.2021Renewal fee patent year 11
25.03.2022Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL26.10.2022
EE26.10.2022
LV26.10.2022
MC26.10.2022
SM26.10.2022
IS26.02.2023
LU27.05.2023
[2024/08]
Former [2023/37]AL26.10.2022
EE26.10.2022
LV26.10.2022
SM26.10.2022
IS26.02.2023
Former [2023/34]EE26.10.2022
LV26.10.2022
SM26.10.2022
IS26.02.2023
Former [2023/33]LV26.10.2022
SM26.10.2022
IS26.02.2023
Former [2023/27]LV26.10.2022
IS26.02.2023
Former [2023/23]LV26.10.2022
Documents cited:Search[E]EP2578233  (NAT CANCER CT [JP], et al) [E] 1-12 * the whole document *;
 [XY]  - J. VINCENT ET AL, "5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity", CANCER RESEARCH, (20100415), vol. 70, no. 8, doi:10.1158/0008-5472.CAN-09-3690, ISSN 0008-5472, pages 3052 - 3061, XP055080069 [X] 1,7 * abstract * * page 3052, column r, paragraph 1 * [Y] 2-6,8-12

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-09-3690
 [XY]  - E. SUZUKI, "Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity", CLINICAL CANCER RESEARCH, (20050915), vol. 11, no. 18, doi:10.1158/1078-0432.CCR-05-0883, ISSN 1078-0432, pages 6713 - 6721, XP055080337 [X] 1,7 * abstract * * page 6713, column r - page 6714, column l, paragraph 1 * * page 6715, column l, paragraph 4 * * page 6715, column r, paragraph 2 - paragraph 4 * * page 6718 - page 6719, column l, paragraph 1 * * page 6719, column l, paragraph 2 - paragraph 3 * * page 6719, column r, paragraph 2 - page 6720, column l, paragraph 1 * * page 6720, column r, paragraph 2 * * page 6721, column r, paragraph 2 * [Y] 2-6,8-12

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-05-0883
 [XY]  - DULUC DOROTH�E ET AL, "Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (20071215), Database accession no. NLM17848619, XP002713350 [X] 1,3-5,7 * abstract * [Y] 2-5,8-12

DOI:   http://dx.doi.org/10.1182/blood-2007-02-072587
    [ ] - BLOOD 15 DEC 2007, (20071215), vol. 110, no. 13, ISSN 0006-4971, pages 4319 - 4330
 [XY]  - F. CABILLIC ET AL, "Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte?dendritic cell cross-talk", CLINICAL & EXPERIMENTAL IMMUNOLOGY, (20061201), vol. 146, no. 3, doi:10.1111/j.1365-2249.2006.03212.x, ISSN 0009-9104, pages 518 - 523, XP055080239 [X] 1,3-5,7 * abstract * [Y] 2-5,8-12

DOI:   http://dx.doi.org/10.1111/j.1365-2249.2006.03212.x
 [XY]  - BECKER Y, "Molecular immunological approaches to biotherapy of human cancers - A review, hypothesis and implications", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, (20060301), vol. 26, no. 2A, ISSN 0250-7005, pages 1113 - 1134, XP008087034 [X] 1,3-5,7 * abstract * [Y] 2-5,8-12
 [XIY]  - ZANGARI MAURIZIO ET AL, "Immunomodulatory drugs in multiple myeloma.", EXPERT OPINION ON INVESTIGATIONAL DRUGS NOV 2005, (200511), vol. 14, no. 11, ISSN 1744-7658, pages 1411 - 1418, XP002713351 [X] 1,7 * abstract * [I] 3-5 [Y] 2-5,8-12

DOI:   http://dx.doi.org/10.1517/13543784.14.11.1411
 [A]  - PORGADOR ET AL, "INTERLEUKIN 6 GENE TRANSFECTION INTO LEWIS LUNG CARCINOMA TUMOR CELL SUPPRESSES THE MALIGNANT PHENOTYPE AND CONFERS IMMUNOTHERAPEUTIC COMPETENCE AGAINST PARENTAL METASTATIC CELLS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (19920701), vol. 52, ISSN 0008-5472, pages 3679 - 3686, XP002104479 [A] 1-12 * abstract *
 [A]  - CHERYL A. ARMSTRONG ET AL, "Melanoma-Derived Interleukin 6 Inhibits In Vivo Melanoma Growth.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, (19940301), vol. 102, no. 3, doi:10.1111/1523-1747.ep12371782, ISSN 0022-202X, pages 278 - 284, XP055080261 [A] 1-12 * abstract *

DOI:   http://dx.doi.org/10.1111/1523-1747.ep12371782
 [A]  - TANAKA ET AL, "The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector.", CANCER RESEARCH, (19970401), vol. 57, no. 7, ISSN 0008-5472, pages 1335 - 1343, XP055080260 [A] 1-12 * abstract *
 [A]  - SEBBA ANTHONY, "Tocilizumab: the first interleukin-6-receptor inhibitor.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (20080801), Database accession no. NLM18653811, XP002713356 [A] 1-12 * abstract *

DOI:   http://dx.doi.org/10.2146/ajhp070449
    [ ] - AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY : AJHP : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 1 AUG 2008, (20080801), vol. 65, no. 15, ISSN 1535-2900, pages 1413 - 1418
 [A]  - AKIRA S ET AL, "The evidence for interleukin-6 as an autocrine growth factor in malignancy.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (199202), Database accession no. NLM1643291, XP002713357 [A] 1-12 * abstract *
    [ ] - SEMINARS IN CANCER BIOLOGY FEB 1992, (199202), vol. 3, no. 1, ISSN 1044-579X, pages 17 - 26
International search[X]WO2009148148  (JAPAN GOVERNMENT [JP], et al);
 [X]JP2010527615  (ALDER BIOPHARMACEUTICALS, INC.);
 [X]  - SOCIETY FOR FUNDAMENTAL CANCER IMMUNOLOGY, (2006), vol. 10TH, page 49, XP008168592
 [X]  - DAI 68 KAI ANNUAL MEETING OF THE JAPAN CANCER ASSOCIATION, (20090831), page 286, XP008169109
 [X]  - ANNUAL REVIEW MEN'EKI, (1999), vol. 1999, pages 257 - 269, XP008169107
 [X]  - J.IMMNOL., (1995), vol. 154, no. 5, pages 2281 - 2290, XP055100942
ExaminationWO2009148148
 EP2305306
    - Thomas R Ulich ET AL, "Intratracheal Injection of Endotoxin and Cytokines II. Interleukin-6 and Transforming Growth Factor Beta Inhibit Acute Inflammation", American Journal of Pathology, (19910501), vol. 138, pages 1097 - 1101, XP055490383
    - SLEEMAN J ET AL, "Cancer metastasis as a therapeutic target", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM NL, vol. 46, no. 7, ISSN 0959-8049, (20100501), pages 1177 - 1180, (20100320), XP027027291
    - Sacchi A ET AL, "Treatment with monoclonal antibody to a Lewis lung carcinoma-associated antigen: different effects on primary tumor and its metastases", Cancer Treat Rep., (19850101), vol. 69, no. 9, pages 985 - 991, XP055784480
    - TOSHIYUKI OGATA ET AL, "Anti-IL-6 receptor antibody does not ameliorate radiation pneumonia in mice", EXPERIMENTAL AND THERAPEUTIC MEDICINE, GR, (20120801), vol. 4, no. 2, doi:10.3892/etm.2012.582, ISSN 1792-0981, pages 273 - 276, XP055490373

DOI:   http://dx.doi.org/10.3892/etm.2012.582
    - OGATA TOSHIYUKI ET AL, "Early administration of IL-6RA does not prevent radiation-induced lung injury in mice", RADIATION ONCOLOGY, BIOMED CENTRAL LTD, LO, (20100407), vol. 5, no. 1, doi:10.1186/1748-717X-5-26, ISSN 1748-717X, page 26, XP021081382

DOI:   http://dx.doi.org/10.1186/1748-717X-5-26
    - LATULIPPE EVA ET AL, "Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 62, no. 15, ISSN 0008-5472, (20020801), pages 4499 - 4506, XP002507791
    - Lancaster J.M. ET AL, "Identification of genes associated with ovarian cancer metastasis using microarray expression analysis", INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, US, (20060901), vol. 16, no. 5, doi:10.1111/j.1525-1438.2006.00660.x, ISSN 1048-891X, pages 1733 - 1745, XP055784486

DOI:   http://dx.doi.org/10.1111/j.1525-1438.2006.00660.x
    - R Bellomo, "The cytokine network in the critically Ill.", Anaesth Intensive Care, 20(3), (19920801), pages 288 - 302, URL: http://www.ncbi.nlm.nih.gov/pubmed/1524167, (20180705), XP055490396
    - ANDO KATSUTOSHI ET AL, "Tocilizumab, a Proposed Therapy for the Cachexia of Interleukin6-Expressing Lung Cancer", PLOS ONE, (20140710), vol. 9, no. 7, doi:10.1371/journal.pone.0102436, page e102436, XP055784490

DOI:   http://dx.doi.org/10.1371/journal.pone.0102436
    - PORGADOR ET AL, "INTERLEUKIN 6 GENE TRANSFECTION INTO LEWIS LUNG CARCINOMA TUMOR CELL SUPPRESSES THE MALIGNANT PHENOTYPE AND CONFERS IMMUNOTHERAPEUTIC COMPETENCE AGAINST PARENTAL METASTATIC CELLS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (19920701), vol. 52, ISSN 0008-5472, pages 3679 - 3686, XP002104479
    - AKIRA S ET AL, "The evidence for interleukin-6 as an autocrine growth factor in malignancy.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (199202), Database accession no. NLM1643291, XP002713357
    - AKIRA S ET AL, "The evidence for interleukin-6 as an autocrine growth factor in malignancy.", SEMINARS IN CANCER BIOLOGY FEB 1992, (199202), vol. 3, no. 1, ISSN 1044-579X, pages 17 - 26
    - SEBBA ANTHONY, "Tocilizumab: the first interleukin-6-receptor inhibitor.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (20080801), Database accession no. NLM18653811, XP002713356

DOI:   http://dx.doi.org/10.2146/ajhp070449
    - SEBBA ANTHONY, "Tocilizumab: the first interleukin-6-receptor inhibitor.", AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY : AJHP : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 01 AUG 2008, (20080801), vol. 65, no. 15, ISSN 1535-2900, pages 1413 - 1418
    - ZANGARI MAURIZIO ET AL, "Immunomodulatory drugs in multiple myeloma.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (200511), Database accession no. NLM16255679
    - ZANGARI MAURIZIO ET AL, "Immunomodulatory drugs in multiple myeloma.", EXPERT OPINION ON INVESTIGATIONAL DRUGS NOV 2005, (200511), vol. 14, no. 11, doi:10.1517/13543784.14.11.1411, ISSN 1744-7658, pages 1411 - 1418, XP002713351

DOI:   http://dx.doi.org/10.1517/13543784.14.11.1411
    - DULUC DOROTH�E ET AL, "Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (20071215), Database accession no. NLM17848619, XP002713350

DOI:   http://dx.doi.org/10.1182/blood-2007-02-072587
    - DULUC DOROTH�E ET AL, "Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells.", BLOOD 15 DEC 2007, (20071215), vol. 110, no. 13, doi:10.1182/blood-2007-02-072587, ISSN 0006-4971, pages 4319 - 4330, XP055475444

DOI:   http://dx.doi.org/10.1182/blood-2007-02-072587
by applicantUS3773919
 EP0058481
 EP0125023
 EP0133988
 EP0239400
 EP0325474
 JPH0159878B
 EP0411946
 JPH03139293
 JPH03155795
 JPH03219894
 WO9201047
 WO9203918
 WO9219759
 WO9220791
 WO9306213
 WO9311236
 WO9312227
 WO9319172
 WO9402602
 WO9411523
 WO9425585
 WO9501438
 WO9515388
 WO9611020
 WO9612503
 WO9617869
 WO9618648
 WO9630394
 WO9634096
 WO9633735
 US5571513
 JPH08291199
 WO9842377
 WO9947170
 WO0010607
 WO0203492
 WO02080969
 WO2009041621
 WO2009148148
    - HIRANO, T. ET AL., NATURE, (1986), vol. 324, pages 73 - 76
    - AKIRA, S. ET AL., ADV. IN IMMUNOLOGY, (1993), vol. 54, pages 1 - 78
    - LOTZ, M. ET AL., J. EXP. MED., (1988), vol. 167, pages 1253 - 1258
    - TAGA, T. ET AL., J. EXP. MED., (1987), vol. 166, pages 967 - 981
    - YAMASAKI, K. ET AL., SCIENCE, (1987), vol. 241, pages 825 - 828
    - YASUKAWA, K. ET AL., J. BIOCHEM., (1990), vol. 108, pages 673 - 676
    - EUR. J. BIOCHEM, (1987), vol. 168, pages 543 - 550
    - J. IMMUNOL., (1988), vol. 140, pages 1534 - 1541
    - AGR. BIOL. CHEM., (1990), vol. 54, pages 2685 - 2688
    - KEARNEY, J. F. ET AL., J. IMMUNOL, (1979), vol. 123, pages 1548 - 1550
    - CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, (1978), vol. 81, pages 1 - 7
    - KOHLER, G.; MILSTEIN, C., EUR. J. IMMUNOL., (1976), vol. 6, pages 511 - 519
    - MARGULIES, D. H. ET AL., CELL, (1976), vol. 8, pages 405 - 415
    - SHULMAN, M. ET AL., NATURE, (1978), vol. 276, pages 269 - 270
    - DE ST. GROTH, S. F. ET AL., J. IMMUNOL. METHODS, (1980), vol. 35, pages 1 - 21
    - TROWBRIDGE, 1. S., J. EXP. MED., (1978), vol. 148, pages 313 - 323
    - GALFRE, G. ET AL., NATURE, (1979), vol. 277, pages 131 - 133
    - KOHLER, G.; MILSTEIN, C., METHODS ENZYMOL., (1981), vol. 73, pages 3 - 46
    - CHIRGWIN, J. M. ET AL., BIOCHEMISTRY, (1979), vol. 18, pages 5294 - 5299
    - CHOMCZYNSKI, P. ET AL., ANAL. BIOCHEM., (1987), vol. 162, pages 156 - 159
    - FROHMAN, M. A. ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 8998 - 9002
    - BELYAVSKY, A. ET AL., NUCLEIC ACIDS RES., (1989), vol. 17, pages 2919 - 2932
    - SATO, K. ET AL., CANCER RES., (1993), vol. 53, pages 851 - 856
    - MULLIGAN, R. C. ET AL., NATURE, (1979), vol. 277, pages 108 - 114
    - MIZUSHIMA, S.; NAGATA S., NUCLEIC ACIDS RES., (1990), vol. 18, page 5322
    - WARD, E. S. ET AL., NATURE, (1989), vol. 341, pages 544 - 546
    - WARD, E. S. ET AL., FASEB J., (1992), vol. 6, pages 2422 - 2427
    - BETTER, M. ET AL., SCIENCE, (1988), vol. 240, pages 1041 - 1043
    - LEI, S. P. ET AL., J. BACTERIOL., (1987), vol. 169, pages 4379 - 4383
    - EBERT, K. M. ET AL., BIO/TECHNOLOGY, (1994), vol. 12, pages 699 - 702
    - MAEDA, S. ET AL., NATURE, (1985), vol. 315, pages 592 - 594
    - JULIAN, K. -C. MA ET AL., EUR. J. IMMUNOL., (1994), vol. 24, pages 131 - 138
    - CO, M. S. ET AL., J. IMMUNOL., (1994), vol. 152, pages 2968 - 2976
    - BETTER, M.; HORWITZ, A. H., METHODS IN ENZYMOLOGY, (1989), vol. 178, pages 476 - 496
    - PLUECKTHUN, A.; SKERRA, A., METHODS IN ENZYMOLOGY, (1989), vol. 178, pages 497 - 515
    - LAMOYI, E., METHODS IN ENZYMOLOGY, (1989), vol. 121, pages 652 - 663
    - ROUSSEAUX, J. ET AL., METHODS IN ENZYMOLOGY, (1989), vol. 121, pages 663 - 666
    - BIRD, R. E. ET AL., TIBTECH, (1991), vol. 9, pages 132 - 137
    - HUSTON, J. S. ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 5883
    - MATSUDA, T. ET AL., EUR. J. IMMUNOL., (1998), vol. 18, pages 951 - 956
    - SATO K ET AL., THE ABSTRACTS OF THE 21ST ANNUAL MEETING OF THE JAPANESE SOCIETY FOR IMMUNOLOGY, (1991), vol. 21, page 166
    - TAMURA, T. ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 11924 - 11928
    - HIRATA, Y. ET AL., J. IMMUNOL., (1989), vol. 143, pages 2900 - 2906
    - VRIEND ET AL., J. MOL. GRAPHICS, (1990), vol. 8, pages 52 - 56
    - BRAKENHOFF ET AL., J. BIOL. CHEM., (1994), vol. 269, pages 86 - 93
    - SAVINO ET AL., EMBO J., (1994), vol. 13, pages 1357 - 1367
    - "Continuation of Development of Pharmaceuticals", Peptide Synthesis, HIROKAWA SHOTEN, (1991), vol. 14
    - LANGER ET AL., J. BIOMED. MATER. RES., (1981), vol. 15, pages 167 - 277
    - LANGER, CHEM. TECH., (1982), vol. 12, pages 98 - 105
    - SIDMAN ET AL., BIOPOLYMERS, (1983), vol. 22, pages 547 - 556
OppositionWO9620728
 EP0800829
 WO2007061029
 EP1967209
 WO2009148148
 US2010129357
 EP2305306
    - Kuna Mareina, Jono Hirofumi, Shinriki Satoru, Yano Shigetoshi, Nakamura Hideo, Makino Keishi, Hide Takuichiro, Muta Daisuke, Ueda Mitsuharu, 0ta Kazutoshi, Ando Yukio, Kuratsu Jun-Ichi, "Anti tumor effect of humanized anti-interleukin-6 receptor antibody {tocilizumab) on glioma cell proliferation Laboratory investigation", J Neurosurg ., (20090801), vol. 111, no. 2, doi:10.3171/2008.12.JNS081284, pages 219 - 225, XP093090642

DOI:   http://dx.doi.org/10.3171/2008.12.JNS081284
    - Satoru Shinriki, Hirofumi Jono, Kazutoshi Ota, Mitsuharu Ueda, Mareina Kudo, Tomoko Ota, Yuichi Oike, Motoyoshi Endo, Mutsuko Ibusuki, Akimitsu Hiraki, Hideki Nakayama, Yoshihiro Yoshitake, Masanori Shinohara and Yukio Ando, "Humanized Anti-Interleukin-6 Receptor Antibody Suppresses Tumor Angiogenesis and In vivo Growth of Human Oral Squamous Cell Carcinoma", Clinical Cancer Research, US, (20090901), vol. 15, no. 17, doi:10.1158/1078-0432.CCR-09-0287, ISSN 1078-0432, pages 5426 - 5434, XP002628465

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-09-0287
    - Sinibaldi Edoardo, Argiolas Alfredo, Puleo Gian Luigi, Mazzolai Barbara, "Another Lesson from Plants: The Forward Osmosis-Based Actuator", PLOS ONE, US , (20140714), vol. 9, no. 7, doi:10.1371/journal.pone.0102461, ISSN 1932-6203, pages 1 - 12, XP002807071
    - Zaki N H , Nemetij J A , Trikha M, "CNTO 328, A monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice", International Journal of Cancer, US , (20040101), vol. 111, doi:10.1002/ijc.20270, ISSN 0020-7136, pages 592 - 595, XP003012697

DOI:   http://dx.doi.org/10.1002/ijc.20270
    - Mori Kazushige, Fujimoto-Ouchi Kaori, Onuma Etsuro, Noguchi Mariko, Shimonaka Yasushi, Yasuno Hideyuki, Nishimura Takashi, "Novel models of cancer-related anemia in mice inoculated with IL-6-producing tumor cells", Biomedical Research, Sapporo Japan , (20090101), vol. 30, no. 1, doi:10.2220/biomedres.30.47, ISSN 0388-6107, pages 47 - 51, XP093090643

DOI:   http://dx.doi.org/10.2220/biomedres.30.47
    - Mini E., S Nobili, B Caciagli, I Landini, T Mazzei, "Cellular pharmacology of gemcitabine", Annals of oncology, (20060531), vol. 17, doi:10.1093/annonc/mdj941, pages 1 - 12, XP055895651

DOI:   http://dx.doi.org/10.1093/annonc/mdj941
    - Yoshio-Hoshino Naoko, Adachi Yasuo, Aoki Chieko, Pereboev Alexander, Curiel David T., Nishimoto Norihiro, "Establishment of a New Interleukin-6 (IL-6) Receptor Inhibitor Applicable to the Gene Therapy for IL-6-Dependent Tumor", Cancer research, US, (20070201), vol. 67, no. 3, doi:10.1158/0008-5472.CAN-06-3641, ISSN 0008-5472, pages 871 - 875, XP093090644

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-06-3641
    - Ara, T. ; DeClerck, Y.A., "Interleukin-6 in bone metastasis and cancer progression", European Journal of Cancer, Amsterdam NL , (20100501), vol. 46, no. 7, ISSN 0959-8049, pages 1223 - 1231, XP027027297
    - Muenchen H J, Quigley M M, Pilat M J, Lehr J E, Brumfield S K, Mahoney M, Pienta K J, "The study of gemcitabine in combination with other chemotherapeutic agents as an effective treatment for prostate cancer", Anticancer research, GR , (20000301), vol. 20, no. 2A, ISSN 0250-7005, pages 735 - 740, XP093090647
    - C J Van Moorsel , G Veerman, A M Bergman, A Guechev, J B Vermorken, P E Postmus, G J Peters, "Combination chemotherapy studies with gemcitabine", Seminars in Oncology, (19970101), vol. 24, no. Suppl 7, pages 17 - 23, XP093090648
    - Anonymous, "COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN lJSE (CHMP) OPINION FOLLOWING AN ARTICLE 30 REFERRAL FOR Gemzar", European Medicines Agency Evaluation of Medicines for Human Use, (20080924), pages 1 - 45, XP093090663
    - Anonymous, "Fibrosarcoma", (20220303), pages 1 - 3, Wikipedia , URL: https://en.wikipedia.org/w/index.php?title=Fibrosarcoma&oldid=1075103255, (20231011), XP093090653
    - Anonymous, "Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients (PACTO)", (20160506), pages 1 - 7, Clinicaltrials, URL: https://clinicaltrials.gov/study/NCT02767557?tab=history&a=1, (20231011), XP093090655
    - Markovna Inna, Chen, Julia S. Johansen, Susann Theile, Kasper Madsen, Olav Da;Ani, Torben Lorentzen, Teresa Zimmers, Dorte Nielsen, "4147 Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer(PACTO)", American Society of Clinical Oncology, (20230619), pages 1 - 1, XP093090661
    - Almand Bond, Resser John R, Lindman Brian, Nadaf Sorena, Clark Joseph I, Kwon Eugene D, Carbone David P, Gabrilovich Dmitry I, "Clinical Significance of Defective Dendritic Cell Differentiation in Cancer ", Clinical Cancer Research, (20000101), vol. 6, pages 1755 - 1766, XP093147218
    - Almand Bond, Clark Joseph I., Nikitina Ekaterina, Van Beynen James, English Nicholas R., Knight Stella C., Carbone David P., Gabrilovich Dmitry I., "Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer", The Journal of Immunology, Williams & Wilkins Co., US, US , (20010101), vol. 166, no. 1, doi:10.4049/jimmunol.166.1.678, ISSN 0022-1767, pages 678 - 689, XP093147220

DOI:   http://dx.doi.org/10.4049/jimmunol.166.1.678
    - Kentaro Sumida; Daiko Wakita; Yoshinori Narita; Kazutaka Masuko; Satoshi Terada; Kazue Watanabe; Takayuki Satoh; Hidemitsu Kitamura; Takashi Nishimura, "Anti‐IL‐6 receptor mAb eliminates myeloid‐derived suppressor cells and inhibits tumor growth by enhancing T‐cell responses", European Journal of Immunology, Wiley-VCH, Hoboken, USA, Hoboken, USA, (20120803), vol. 42, no. 8, doi:10.1002/eji.201142335, ISSN 0014-2980, pages 2060 - 2072, XP071226591

DOI:   http://dx.doi.org/10.1002/eji.201142335
    - E. Suzuki, "Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity", Clinical Cancer Research, Association for Cancer Research, (20050915), vol. 11, no. 18, doi:10.1158/1078-0432.CCR-05-0883, ISSN 10780432, pages 6713 - 6721, XP055080337

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-05-0883
    - Gabrilovich Dmitry I.; Nagaraj Srinivas, "Myeloid-derived suppressor cells as regulators of the immune system", Nature Reviews Immunology, Nature Publishing Group UK, London, London, (20090301), vol. 9, no. 3, doi:10.1038/nri2506, ISSN 1474-1733, pages 162 - 174, XP037923140

DOI:   http://dx.doi.org/10.1038/nri2506
    - Stephanie K. Bunt, "Reduced Inflammation in the Tumor Microenvironment Delays the Accumulation of Myeloid-Derived Suppressor Cells and Limits Tumor Progression", Cancer research, American Association for Cancer Research, US, US, (20071015), vol. 67, no. 20, doi:10.1158/0008-5472.CAN-07-2354, ISSN 0008-5472, pages 10019 - 10026, XP093163596

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-07-2354
    - OSTRAND-ROSENBERG SUZANNE, SINHA PRATIMA, "Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer", The Journal of Immunology, Williams & Wilkins Co., US, US , (20090415), vol. 182, no. 8, doi:10.4049/JIMMUNOL.0802740, ISSN 0022-1767, pages 4499 - 4506, XP002588069

DOI:   http://dx.doi.org/10.4049/JIMMUNOL.0802740
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.